REAL LIFE ANTICOAGULANT TREATMENT FOR STROKE PREVENTION IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION

被引:6
作者
Sabau, Monica [1 ,2 ]
Tica, Otilia [1 ,2 ]
Chetan, Filip [3 ]
Tica, Ovidiu [1 ]
Comanescu, Alexandra [1 ,2 ]
Antal, Liana [1 ]
Muresan, Mariana [1 ,2 ]
Enachescu, Viorela [4 ]
Diaconu, Camelia [5 ]
Bidian, Cristina [6 ]
机构
[1] Univ Oradea, Fac Med & Pharm, Oradea, Romania
[2] Emergency Cty Clin Hosp Oradea, Oradea, Romania
[3] Emergency Univ Hosp, Bucharest, Romania
[4] Univ Med & Pharm Craiova, Craiova, Romania
[5] Univ Med & Pharm Carol Davila, Bucharest, Romania
[6] Iuliu Hatieganu Univ Med & Pharm Cluj Napoca, Cluj Napoca, Romania
关键词
stroke; atrial fibrillation; cardioembolism; WARFARIN; MANAGEMENT; EFFICACY; QUALITY; THERAPY; EVENTS; SAFETY; AGE;
D O I
10.31925/farmacia.2020.5.19
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Atrial fibrillation (AF) represents the most frequent cause of cardioembolic stroke. The aim of the study was to evaluate the patterns of anticoagulant treatment in patients admitted for stroke due to non-valvular atrial fibrillation (NVAF). The main inclusion criteria in the study was the diagnosis of cardioembolic stroke in patients admitted to our hospital between November 2016 and February 2017. We evaluated different subtypes of AF related to stroke. A number of 108 patients with NVAF were included. Of the 90 patients known with NVAF, 41 had received recommendation for anticoagulant therapy, but only 27 followed the treatment. An important percentage of patients with stroke, treated with vitamin K antagonists (VKA), were not optimally anticoagulated, being at risk both for thromboembolic risk and haemorrhagic events. An important percentage of patients with stroke, treated with VKA, are not optimally controlled (INR outside the therapeutic range), exposing them at risk for thromboembolic and also haemorrhagic events. In real life settings, in Romania, only a small number of patients with NVAF receive NOAC treatment.
引用
收藏
页码:912 / 918
页数:7
相关论文
共 25 条
  • [1] Adams CD, 2012, IRWIN RIPPES INTENSI, P1224
  • [2] Changes in Oral Anticoagulant Prescribing for Stroke Prevention in Patients With Atrial Fibrillation
    Admassie, Endalkachew
    Chalmers, Leanne
    Bereznicki, Luke R.
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2017, 120 (07) : 1133 - 1138
  • [3] Oral Anticoagulant Therapy Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
    Ageno, Walter
    Gallus, Alexander S.
    Wittkowsky, Ann
    Crowther, Mark
    Hylek, Elaine M.
    Palareti, Gualtiero
    [J]. CHEST, 2012, 141 (02) : E44S - E88S
  • [4] Daina L, 2015, FARMACIA, V63, P407
  • [5] Daina LG, 2017, FARMACIA, V65, P360
  • [6] DIACONU C, 2014, ARCH BALK MED UNION, V49, P247
  • [7] Diaconu C. C., 2018, ARCH BALK MED UNION, V53, P177
  • [8] Novel Oral Anticoagulants in Atrial Fibrillation: A Meta-analysis of Large, Randomized, Controlled Trials vs Warfarin
    Dogliotti, Ariel
    Paolasso, Ernesto
    Giugliano, Robert P.
    [J]. CLINICAL CARDIOLOGY, 2013, 36 (02) : 61 - 67
  • [9] Prevalence of diagnosed atrial fibrillation in adults - National implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study
    Go, AS
    Hylek, EM
    Phillips, KA
    Chang, YC
    Henault, LE
    Selby, JV
    Singer, DE
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (18): : 2370 - 2375
  • [10] Efficacy and Safety of Rivaroxaban Compared With Warfarin Among Elderly Patients With Nonvalvular Atrial Fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)
    Halperin, Jonathan L.
    Hankey, Graeme J.
    Wojdyla, Daniel M.
    Piccini, Jonathan P.
    Lokhnygina, Yuliya
    Patel, Manesh R.
    Breithardt, Guenter
    Singer, Daniel E.
    Becker, Richard C.
    Hacke, Werner
    Paolini, John F.
    Nessel, Christopher C.
    Mahaffey, Kenneth W.
    Califf, Robert M.
    Fox, Keith A. A.
    [J]. CIRCULATION, 2014, 130 (02) : 138 - U45